Achieve Life Sciences Inc
ACHV
NASDAQ
Biotechnology
$7.59
USD
+0.34 (+4.69%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $725.46M
Volume 1.7M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-114.04M
TTM
-126.2%
YoY
Operating Cash Flow
$-47.02M
TTM
-18.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.9 | 9.4 | 10.9 | 7.2 | 14.6 |
Other Operating Expenses | 0.1 | 0.0 | 0.4 | 0.0 | 0.1 |
Total Operating Expenses | 12.7 | 14.7 | 15.1 | 10.5 | 18.5 |
Operating Income | -12.7 | -14.7 | -15.1 | -10.5 | -18.5 |
EBITDA | -12.6 | -14.6 | -14.7 | -10.4 | -18.4 |
Other Income / Expense | -0.1 | -0.1 | 0.3 | 0.3 | -57.5 |
Total Other Income / Expense | -0.1 | 0.3 | 0.5 | 0.3 | -56.3 |
Income Before Income Taxes | -12.7 | -14.4 | -14.7 | -10.2 | -74.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -12.7 | -14.4 | -14.7 | -10.2 | -74.8 |
Consolidated Net Income / Loss | -12.7 | -14.4 | -14.7 | -10.2 | -74.8 |
Net Income Attributable to Common Shareholders | -12.7 | -14.4 | -14.7 | -10.2 | -74.8 |
Basic EPS | -$0.37 | -$0.28 | -$0.27 | -$0.19 | -$0.80 |
Diluted EPS | -$0.37 | -$0.28 | -$0.27 | -$0.19 | -$0.80 |
Basic Shares Outstanding | 34.7M | 51.0M | 54.0M | 53.4M | 93.5M |
Diluted Shares Outstanding | 34.7M | 51.0M | 54.0M | 53.4M | 93.5M |